U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Monday.
Shares of First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) rose sharply after the company released topline results from Cohort 1 of its Phase 1b clinical trial of ANB033 in celiac disease.
The clinical-stage biotechnology firm designed ANB033 as an investigational, subcutaneously administered CD122 antagonist to block IL-15 and IL-2 signaling on immune cells. During a 14-day gluten challenge, the candidate protected against gluten-induced intestinal damage and prevented symptom aggravation in study subjects.
First Tracks Biotherapeutics shares jumped 18% to $37.36 on Monday.
Here are some other big stocks recording gains in today’s session.
Photo via Shutterstock